Investors
-
April 30, 2024Notice to attend the Annual General Meeting 2024 in Umecrine Cognition ABSTOCKHOLM – April 30, 2024. The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general...
-
April 16, 2024Umecrine Cognition publishes scientific review on the role of endogenous neurosteroids in neuroinflammation and their potential therapeutic effectSTOCKHOLM – April 16, 2024. Umecrine Cognition today announces that the company has co-authored a scientific review article with leading experts in...
-
March 22, 2024Umecrine Cognition’s Phase 1b/2 study of golexanolone in Primary Biliary Cholangitis progresses to Part B following positive safety reviewSTOCKHOLM – March 22, 2024. Umecrine Cognition today announces the successful completion of the first part (Part A) of its ongoing clinical Phase...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.